Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

OBJECTIVES: To study the determinants of the pharmacokinetics (PK) of rituximab (RTX) in patients with ANCA-associated vasculitis (AAV) and its association with clinical outcomes. METHODS: This study included data from 89 patients from the RTX in AAV trial who received the full dose of RTX (four wee...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatology (Oxford)
Main Authors: Cornec, Divi, Kabat, Brian F, Mills, John R, Cheu, Melissa, Hummel, Amber M, Schroeder, Darrell R, Cascino, Matthew D, Brunetta, Paul, Murray, David L, Snyder, Melissa R, Fervenza, Fernando, Hoffman, Gary S, Kallenberg, Cees G M, Langford, Carol A, Merkel, Peter A, Monach, Paul A, Seo, Philip, Spiera, Robert F, St Clair, E William, Stone, John H, Barnidge, David R, Specks, Ulrich
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888934/
https://ncbi.nlm.nih.gov/pubmed/29340623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kex484
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados